Longitudinal progression, metrics, age-dependence, and modifiers of ataxia severity in SCA27B: a multicentre study of 219 patients

Yes
The multicentre observational study analysed 661 assessments from 219 people with SCA27B to examine disease progression, clinical outcome metrics and demographic or genetic modifiers.

This multicentre, intercontinental observational study examined 661 assessments from 219 patients with spinocerebellar ataxia 27B (SCA27B), alongside 390 healthy controls, to investigate the Scale for the Assessment and Rating of Ataxia (SARA), longitudinal progression and potential modifiers of disease severity. Overall progression was 0.54 SARA points per year. Gait, stance and lower-limb impairment were the principal contributors to ataxia severity, while ageing-related motor variability and comorbidities affected assessment. The study also found that larger GAA repeat expansions on the shorter FGF14 allele were associated with faster progression.

publication

Year of publication

2026

Source

eBioMedicine

Author

Andreas Traschütz, Ralf-Dieter Hilgers, Friedrich Erdlenbruch, Christel Depienne, Thomas Wirth, Clarisse Delvallée, Astrid Nümann, Catherine Ashton, David Pellerin, Elisabetta Indelicato, Felix Heindl, Mathilde Renaud, Max Borsche, Marcus Grobe-Einsler, Jennifer Faber, Thomas Klockgether, Ludger Schöls, Bernard Brais, Mathieu Anheim, Dagmar Timmann, Matthis Synofzik

You might also be interested in

November 25 @ 1:00 pm - 2:00 pm
Intended for clinicians, clinical geneticists, researchers, data analysts and ERN members working in rare diseases
Horizon Europe’s 2026–2027 work programme combines broad health research opportunities with changes to applications and new support for taking existing results further.
ERDERA’s third General Assembly brought partners together in Coimbra to review its second year, strengthen connections across the partnership and align priorities for a more integrated and delivery-focused third year.
ERDERA marked the close of its second year with an Open Session on ultra-rare diseases, bringing together European, regulatory and scientific perspectives on how innovation can reach patients.